Pancreatic cancer is one of the deadliest cancers, with a five-year survival rate of only 44% if caught early, dropping down to 3% if it metastasizes. This is largely due to its ability to elude detection.
The CDC estimates that over 6 million people in the U.S. struggle with OUD, and prior research has indicated that only 20% receive treatment for the disorder.
Patients with asymmetries on CEM typically are recalled for additional views, ultrasound and occasionally MRI. But the extra workup might not be necessary.
Clinicians treating COVID-19 patients who have transplanted lungs and lower airway infection should order molecular testing in addition to, or regardless of, imaging findings.
Previously, CMS determined that coverage for patients receiving treatment was dependent on their being enrolled in a CMS-approved clinical trial under coverage with evidence development (CED).
An experimental Alzheimer’s drug therapy has slowed cognitive and functional decline by 27% versus placebo in a double-blind, randomized study of 1,795 individuals with early signs and symptoms of the disease.
Patients with autoimmune hepatitis may be better monitored across disease stages by AI-augmented multiparametric MRI than by liver biopsy, as the imaging has proven less costly and is inherently less risky due to its noninvasiveness.
With 91% sensitivity but only 25% specificity, the tool is worthwhile for clinicians who remain wary of frequent false positives that would send patients with no fractures for unneeded imaging.
